SeekingAlpha · Aug 7, 2026
Praxis: Commercial Launch Could Smash Expectations (Video)
Watch my video presentation of my sum-of-the-parts valuation of Praxis (PRAX) centered on Ulixaâs launch.
PR
NASDAQ · PRAX
Praxis Precision Medicines, Inc.
Healthcare · Biotechnology
$386.33
Down-$17.87 (-4.63%)
Updated Aug 13, 2026, 9:47 PM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.65B
- P/E ratio
- -22.87
- Dividend yield
- 0.00%
- 52-week range
- $238.77 – $386.66
- Volume
- 500.04K
- Avg. volume
- 1.03M
Price performance
PRAX price history
1M range · 21 trading sessions · Daily adjusted prices
PRAX closed at $386.33 after 21 trading sessions, up 21.33% for the selected period.
- Last close
- $386.33
- Period change
- +21.33%
- Period low
- $291.03
- Period high
- $386.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $375.00 | $386.66 | $373.09 | $386.33 | 500.04K |
| Aug 11, 2026 | $367.50 | $372.00 | $361.37 | $370.68 | 320.98K |
| Aug 10, 2026 | $358.72 | $368.31 | $354.70 | $366.96 | 605.06K |
| Aug 7, 2026 | $372.26 | $381.98 | $347.865 | $360.76 | 454.89K |
| Aug 6, 2026 | $350.47 | $382.54 | $343.73 | $370.16 | 1.51M |
| Aug 5, 2026 | $315.00 | $320.68 | $308.17 | $319.23 | 274.92K |
| Aug 4, 2026 | $307.59 | $313.06 | $301.40 | $310.07 | 326.9K |
| Aug 3, 2026 | $300.92 | $307.56 | $292.89 | $305.51 | 315K |
| Jul 31, 2026 | $308.74 | $310.15 | $293.2225 | $307.83 | 385.17K |
| Jul 30, 2026 | $298.48 | $311.60 | $293.49 | $307.75 | 516.3K |
| Jul 29, 2026 | $302.34 | $303.75 | $287.935 | $291.03 | 339.74K |
| Jul 28, 2026 | $316.96 | $316.96 | $290.0901 | $295.81 | 438.62K |
| Jul 27, 2026 | $325.30 | $330.0033 | $315.70 | $315.80 | 296.06K |
| Jul 24, 2026 | $322.29 | $327.505 | $314.615 | $325.30 | 282.68K |
| Jul 23, 2026 | $308.00 | $323.2475 | $305.00 | $322.40 | 325.38K |
| Jul 22, 2026 | $311.52 | $317.45 | $308.06 | $312.10 | 229.41K |
| Jul 21, 2026 | $306.11 | $320.60 | $304.00 | $317.87 | 229.91K |
| Jul 20, 2026 | $315.00 | $325.6575 | $304.19 | $304.43 | 233.35K |
| Jul 17, 2026 | $299.16 | $322.2625 | $299.16 | $314.41 | 282.21K |
| Jul 16, 2026 | $314.53 | $318.77 | $303.28 | $308.20 | 362.65K |
| Jul 15, 2026 | $321.46 | $325.4099 | $312.60 | $318.42 | 253.56K |
Latest PRAX news
The latest Smart Investors Daily articles mentioning PRAX.
Stock researchCompany · Overview
PRAX research
Overview
Company profile and research snapshot.
Company profile
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $403.80
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 6, 2026 | Needham | Buy | — |
| Jul 29, 2026 | BTIG | Buy | — |
| Jul 13, 2026 | Goldman Sachs | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.
Benzinga · Aug 7, 2026
Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362
Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and raises the price target from $323 to $362.
SeekingAlpha · Aug 7, 2026
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsMarcio Souza - President, CEO & DirectorTim...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
